First Manhattan’s Kiniksa Pharmaceuticals KNSA Stock Holding History

First Manhattan’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-63,976	Closed	-$866K	–	1367
2019 Q2	$866K	Buy	63,976 +25,970	+68%	+$403K	﹤0.01%	456
2019 Q1	$686K	Buy	38,006 +38,000	+633,333%	+$734K	﹤0.01%	502
2018 Q4	$0	Hold	6	–	–	﹤0.01%	1410
2018 Q3	$0	Buy	+6	New	+$117	﹤0.01%	1421

Other funds holding KNSA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Manhattan's KNSA Position: Q3 2019 in Review

First Manhattan sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2019, closing a stake of 63,976 shares — an estimated $866K sold.

First Manhattan first reported a position in KNSA in Q3 2018 and held it in 4 quarters. The position peaked at $866K in Q2 2019. 54 funds tracked by Wall St. Rank hold KNSA as of Q3 2019.

First Manhattan reported no remaining Kiniksa Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
First Manhattan sold 63,976 Kiniksa Pharmaceuticals shares in Q3 2019, an estimated $866K.
First Manhattan first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and held it in 4 quarters.
First Manhattan's Kiniksa Pharmaceuticals position peaked at $866K in Q2 2019.
54 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2019.

Based on First Manhattan's 13F filing for Q3 2019, filed 13 Nov 2019.